Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.45 |
| ▸ | NPEPPS | P55786 | 3/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.43 |
| ▸ | ANPEP | P15144 | 2/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822303 | 1.00 | HINT1 (0.48) | HINT1HPGDADORA3NPEPPSSLC29A1 | |
| SCHEMBL19035636 | 1.00 | HINT1 (0.48) | HINT1HPGDADORA3NPEPPSSLC29A1 | |
| SCHEMBL16822302 | 1.00 | HINT1 (0.48) | HINT1HPGDADORA3NPEPPSSLC29A1 | |
| SCHEMBL19146430 | 0.87 | HINT1 (0.41) | HINT1HPGDADORA3NPEPPSSLC29A1 | |
| SCHEMBL19035724 | 0.84 | HPGD (0.64) | HINT1HPGDADORA3TP53ADORA2A | |
| SCHEMBL7259250 | 0.84 | HPGD (0.64) | HINT1HPGDADORA3TP53ADORA2A | |
| SCHEMBL16840859 | 0.84 | HPGD (0.64) | HINT1HPGDADORA3TP53ADORA2A | |
| SCHEMBL22571072 | 0.84 | HPGD (0.64) | HINT1HPGDADORA3TP53ADORA2A | |
| SCHEMBL7259261 | 0.84 | HPGD (0.64) | HINT1HPGDADORA3TP53ADORA2A | |
| SCHEMBL19035723 | 0.84 | HPGD (0.64) | HINT1HPGDADORA3TP53ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688715-B2 | Synthetic pGpG analogs, methods of preparation and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-06-27 | — | — | US | disclosed |
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175649-A1 | SYNTHETIC pGpG ANALOGS, METHODS OF PREPARATION AND METHODS OF USE | MRPL21, PGLS, CFTR | HINT1 1449/4885HPGD 341/4885ADORA3 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.